Ceftriaxone
Ceftriaxone is a topic covered in the Johns Hopkins ABX Guide.
To view the entire topic, please log in or purchase a subscription.
Official website of the Johns Hopkins Antibiotic (ABX), HIV, Diabetes, and Psychiatry Guides, powered by Unbound Medicine. Johns Hopkins Guide App for iOS, iPhone, iPad, and Android included. Explore these free sample topics:
-- The first section of this topic is shown below --
INDICATIONS
FDA
FDA
- Lower respiratory tract infections
- Acute bacterial otitis media
- Skin and skin-structure infections
- Urinary tract infections (complicated and uncomplicated)
- Uncomplicated gonorrhea
- Pelvic inflammatory disease
- Septicemia
- Bone and joint infections
- Intra-abdominal infections
- Meningitis and surgical prophylaxis
NON-FDA APPROVED USES
NON-FDA APPROVED USES
- Brain abscess (with metronidazole)
- Appendicitis (with metronidazole)
- Peritonitis: spontaneous bacterial and secondary
- Endocarditis
- Diabetic foot infections (with metronidazole or clindamycin)
- Lyme disease: late Lyme arthritis and neuroborreliosis
- Meningococcal meningitis prophylaxis: 125 mg x1 (< 15 yrs); 250 mg x1 (≥15 yrs)
- Neurosyphilis
- Disseminated GC
-- To view the remaining sections of this topic, please log in or purchase a subscription --
INDICATIONS
FDA
FDA
- Lower respiratory tract infections
- Acute bacterial otitis media
- Skin and skin-structure infections
- Urinary tract infections (complicated and uncomplicated)
- Uncomplicated gonorrhea
- Pelvic inflammatory disease
- Septicemia
- Bone and joint infections
- Intra-abdominal infections
- Meningitis and surgical prophylaxis
NON-FDA APPROVED USES
NON-FDA APPROVED USES
- Brain abscess (with metronidazole)
- Appendicitis (with metronidazole)
- Peritonitis: spontaneous bacterial and secondary
- Endocarditis
- Diabetic foot infections (with metronidazole or clindamycin)
- Lyme disease: late Lyme arthritis and neuroborreliosis
- Meningococcal meningitis prophylaxis: 125 mg x1 (< 15 yrs); 250 mg x1 (≥15 yrs)
- Neurosyphilis
- Disseminated GC
There's more to see -- the rest of this entry is available only to subscribers.